Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TBPH vs DSGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TBPH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

TBPH Overall Winner 6-Pillar Tally: TBPH 6 – 0 DSGN Matrix Metrics: TBPH 9 – 1 DSGN

As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TBPH carries a Unified Composite Score of 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin), whereas DSGN carries 49.8/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. DSGN 49.8/100 HOLD) and 0.48β · 2% Vol risk profile, whereas DSGN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: TBPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.6); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TBPH vs DSGN
TBPH NASDAQ Head-to-Head Winner
Theravance Biopharma, Inc.
Pharmaceutical Preparations
$17.03
+0.0% 1D
Market Cap $884.2M
TTM Revenue $104M
Forward P/E 13.4x
Beta / 30D Vol 0.48β · 2% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 35.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $17.04 · SMA50: $16.96
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
TTM Revenue $33,000
Forward P/E N/M
Beta / 30D Vol 1.32β · 61% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 55.0 Fund 57.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $10.53 · SMA50: $11.58

6-Pillar Scorecard Institutional Category Breakdown (TBPH 6 – 0 DSGN)

Columns: Metric · TBPH · DSGN
1. Valuation Multiples TBPH
Forward P/E 13.4x N/M
Trailing P/E 16.4x N/M
PEG Ratio N/M N/M
EV / Revenue 8.5x N/M
2. Growth & Scale TBPH
Revenue Growth (YoY) -20.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $104M $33,000
Market Cap $884.2M $677.5M
3. Profitability & Quality TBPH
Gross Margin 75.1% N/A
Operating Margin 8.9% 0.0%
Net Profit Margin 51.6% 0.0%
Return on Equity (ROE) 20.9% -36.9%
4. Balance Sheet & Cash Flow TBPH
Cash Generation (TTM) $11M EBITDA -$59M
Cash Flow Margin 10.6% EBITDA Mgn N/A
Net Cash / Leverage $5.58 Book/Sh · 20.9% ROE $13M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TBPH
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 55.0% (16th %ile) 92.0% (13th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat TBPH
OpEx & R&D Intensity 66.2% of Rev ($69M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TBPH (9) vs DSGN (1)
Institutional Metric TBPH DSGN Criterion Row Edge
Market Capitalization
Scale
$884.2M $677.5M Larger Scale TBPH
Trailing P/E Ratio
Valuation
16.4x N/M Lower Multiple TBPH
Forward P/E Ratio
Valuation
13.4x N/M Lower Multiple TBPH
Revenue Growth (YoY)
Growth
-20.9% +0.0% Higher Growth DSGN
Operating Margin (TTM)
Profitability
8.9% 0.0% Higher Margin TBPH
Net Profit Margin
Profitability
51.6% 0.0% Higher Margin TBPH
Return on Equity (ROE)
Capital Efficiency
20.9% -36.9% Higher ROE TBPH
52-Week Range Position
Momentum
50% ($13–$21) 30% ($7–$17) Stronger Trend TBPH
Beta / 30D Volatility
Risk Regime
0.48β · 2% Vol 1.32β · 61% Vol Lower Realized Risk TBPH
Unified Institutional Score
Composite Signal
54.9 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite TBPH
Trailing 12M Revenue (USD)
Operating Scale
$104M $33,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$11M EBITDA ($5.58 Book/Sh · 20.9% ROE) -$59M ($13M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TBPH +18.96 pp
TBPH: +0.12% · DSGN: -18.84%
3M Horizon TBPH +8.91 pp
TBPH: -1.39% · DSGN: -10.3%
6M Horizon DSGN +5.58 pp
TBPH: +14.3% · DSGN: +19.88%
1Y Horizon DSGN +80.2 pp
TBPH: -5.13% · DSGN: +75.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TBPH vs DSGN. Trailing 12-month operating profitability (TBPH 8.9% vs DSGN 0.0%) and valuation multiples (TBPH 13.4x vs DSGN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TBPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$104M
Gross Margin75.1%
Op. Margin8.9%
ROE / Fwd P/E20.9% · 13.4x
DSGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$33,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-36.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TBPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.0%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TBPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DSGN BREAKDOWN
139d in phase · OBV NEUTRAL
Current IV 92.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TBPH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $884.2M market capitalization and 8.9% operating margin.
OpEx & R&D Reinvestment 66.2% of Rev ($69M)
90D Engineering Disclosures 0 Published
DSGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TBPH vs DSGN Key Questions & Quantitative Answers

As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TBPH carries a Unified Composite Score of 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin), whereas DSGN carries 49.8/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. DSGN 49.8/100 HOLD) and 0.48β · 2% Vol risk profile, whereas DSGN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: TBPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.6); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TBPH leads the Growth & Scale pillar: TBPH posts -20.9% YoY revenue growth and +0.0% YoY earnings growth on $104M TTM revenue (75.1% gross margin, 8.9% operating margin), compared with DSGN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TBPH generates $104M in USD-normalized revenue versus $33,000 for DSGN. In operating R&D and SG&A reinvestment, TBPH deploys 66.2% of Rev ($69M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DSGN.

TBPH screens cheaper on headline valuation multiples. TBPH trades at 13.4x Forward P/E, 16.4x Trailing P/E, N/M PEG, and 8.5x EV/Revenue (10.6% EBITDA margin), whereas DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TBPH (20.9% ROE) versus DSGN (-36.9% ROE) capital efficiency.

In options market volatility and institutional positioning, TBPH carries 55.0% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 2% Vol realized risk). By comparison, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.